Cameron Brink achieves visual freedom with the EVO implantable lenses
Basketball Player
Basketball Player

Vision struggles on and off the court
Cameron Brink, a star on the women’s basketball team of Stanford University, faced the daily struggles of glasses and contacts, impacting both her personal and professional life.

EVO ICL: the game-changer
Join her in experiencing the world with newfound clarity and confidence. For those on the fence about EVO ICL, Cameron passionately encourages,
"Talk to your eye doctor today. It's truly a life-changing procedure!"
Ready to embrace a life without the hassle of glasses and contacts? Discover the possibilities with EVO ICL. Call an EVO advisor today to schedule an appointment with an eye doctor near you, and embark on your own journey towards visual freedom!
Cameron Brink has EVO ICL lenses and is sponsored by STAAR Surgical.
Dôležité bezpečnostné informácie pre EVO/EVO+ ICL
EVO/EVO+ ICL je určený na korekciu/zníženie krátkozrakosti do -20 dioptrií (D) a astigmatizmu do 6 D pre pacientov vo veku 21 až 60 rokov, prípadne pre pacientov starších než 21 rokov, ktorí boli už liečení vnútroočnou šošovkou. Implantácia EVO/EVO+ ICL je chirurgický zákrok, a preto so sebou nesie určité riziká. Medzi potenciálne komplikácie/podujatia patria: ďalšie operácie, vznik katarakty, prechodná alebo trvalá strata najlepšej upravenej ostrosti zraku, zvýšený vnútroočný tlak, strata buniek na najvnútornejšom povrchu rohovky, podráždenie spojivky, opuch rohovky, infekcia oka, dislokácie EVO/EVO+ ICL, makulárny edém, nereagujúca zrenička, pupilárny blok, glaukóm, závažný zápal oka, iritída, uveitída, strata sklovca a transplantácia rohovky. Pred zvažovaním zákroku EVO/EVO+ ICL absolvujte kompletné očné vyšetrenie a porozprávajte sa s očným špecialistom o priebehu, zahrňujúc potenciálne prínosy, riziká a možné komplikácie. Porozprávajte sa aj o čase potrebnom na hojenie po zákroku.
Select Your Region
Latin America
Referencie
1. Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
2. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clin Ophthalmol. 2022;16:1541-53.
3. Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2321-2328
4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. Eur J of Ophthalmol. 2007; 17(1): pp. 1-6.
5. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg., Volume 26 , Issue 9 , 1326 - 1331.
6. Albo C, Nasser T, Szynkarski DT, Nguyen N, Mueller B, Libfraind L, Parkhurst G. A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States. Clin Ophthalmol. 2024 Jan 9;18:69-78.
7. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.



